Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Accured Expenses (2016 - 2026)

Lisata Therapeutics filings provide 14 years of Change in Accured Expenses readings, the most recent being $233000.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 112.88% to $233000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$528000.0, a 66.18% increase, with the full-year FY2025 number at -$2.6 million, down 158.29% from a year prior.
  • Change in Accured Expenses hit $233000.0 in Q1 2026 for Lisata Therapeutics, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.4 million in Q4 2023 to a low of -$1.8 million in Q1 2025.
  • Median Change in Accured Expenses over the past 4 years was $137000.0 (2024), compared with a mean of -$249538.5.
  • The widest YoY moves for Change in Accured Expenses: up 151.26% in 2025, down 241.38% in 2025.
  • Lisata Therapeutics' Change in Accured Expenses stood at $1.4 million in 2023, then dropped by 23.83% to $1.1 million in 2024, then tumbled by 241.38% to -$1.5 million in 2025, then skyrocketed by 115.53% to $233000.0 in 2026.
  • The last three reported values for Change in Accured Expenses were $233000.0 (Q1 2026), -$1.5 million (Q4 2025), and $252000.0 (Q3 2025) per Business Quant data.